Ischemix, a privately held pharmaceutical company has completed Phase 1 Human Safety Studies of its drug candidate, CMX-2043. This double-blind escalating-dose trial in healthy volunteers showed no evidence of treatment-related adverse events at doses up to five times those anticipated to be effective in cardiac surgery patients. Based on this excellent safety profile, the company is now moving forward into studies in cardiac surgery patients.
CMX-2043 clinical development is initially targeted at prevention of complications associated with Coronary Artery Bypass Graft (CABG) surgery. Although CABG surgery is routine and performed approximately 500,000 times per year in the US, many patients have a significant complication after the procedure. The cost of such complications can be tens of thousands of dollars in extra procedures, ICU, and hospital stay per patient.
Ischemix is located in Maynard, MA. Its capabilities include chemical synthesis and analysis laboratories as well as facilities for cell culture and biological research. The company has contractual relationships with synthetic, analytical, manufacturing, preclinical and clinical organizations across the United States and in India.
